Influences of interferon-gamma on cell proliferation and interleukin-6 production in Down syndrome derived fibroblasts

Archives of Oral Biology

Volumn 54, Issue 10, 2009, Pages 963-969

  Iwamoto, Tsutomu ^a   Yamada, Aya ^a   Yuasa, Kenji ^b   Fukumoto, Emiko ^a   Nakamura, Takashi ^a   Fujiwara, Taku ^b   Fukumoto, Satoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Down syndrome; Hypersensitivity; IFN ; IL 6

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT PROTEIN; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CELL LINE; CELL PROLIFERATION; DOWN SYNDROME; DRUG EFFECT; FIBROBLAST; HUMAN; METABOLISM; PHOSPHORYLATION;

CELL LINE; CELL PROLIFERATION; DOWN SYNDROME; FIBROBLASTS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RECOMBINANT PROTEINS; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69449085855     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2009.07.009     Document Type: Article

References (43)

1. Desai S.S. Down syndrome: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84 3 (1997) 279-285
2. Kola I., and Hertzog P.J. Animal models in the study of the biological function of genes on human chromosome 21 and their role in the pathophysiology of Down syndrome. Hum Mol Genet 6 10 (1997) 1713-1727
3. Epstein C.J., Korenberg J.R., Anneren G., Antonarakis S.E., Ayme S., Courchesne E., et al. Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet 49 1 (1991) 207-235
4. Sakellari D., Arapostathis K.N., and Konstantinidis A. Periodontal conditions and subgingival microflora in Down syndrome patients. A case-control study. J Clin Periodontol 32 6 (2005) 684-690
5. Zigmond M., Stabholz A., Shapira J., Bachrach G., Chaushu G., Becker A., et al. The outcome of a preventive dental care programme on the prevalence of localized aggressive periodontitis in Down's syndrome individuals. J Intellect Disabil Res 50 Pt 7 (2006) 492-500
6. de Weerd N.A., Samarajiwa S.A., and Hertzog P.J. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282 28 (2007) 20053-20057
7. Farber J.M. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 87 14 (1990) 5238-5242
8. Meissner M., Whiteside T.L., van Kuik-Romein P., Valesky E.M., van den Elsen P.J., Kaufmann R., et al. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation. Br J Dermatol 158 5 (2008) 930-940
9. Ruszczak Z., Detmar M., Imcke E., and Orfanos C.E. Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 95 6 (1990) 693-699
10. Maher S.G., Romero-Weaver A.L., Scarzello A.J., and Gamero A.M. Interferon: cellular executioner or white knight?. Curr Med Chem 14 12 (2007) 1279-1289
11. Kim P.K., Zamora R., Petrosko P., and Billiar T.R. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 1 8 (2001) 1421-1441
12. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 15 (1997) 749-795
13. Tan Y.H., Schneider E.L., Tischfield J., Epstein C.J., and Ruddle F.H. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science 186 4158 (1974) 61-63
14. Tan Y.H. Chromosome 21 and the cell growth inhibitory effect of human interferon preparations. Nature 260 5547 (1976) 141-143
15. Zihni L. Down's syndrome, interferon sensitivity and the development of leukaemia. Leuk Res 18 1 (1994) 1-6
16. Murphy M., Friend D.S., Pike-Nobile L., and Epstein L.B. Tumor necrosis factor-alpha and IFN-gamma expression in human thymus. Localization and overexpression in Down syndrome (trisomy 21). J Immunol 149 7 (1992) 2506-2512
17. Maroun L.E. Interferon action and chromosome 21 trisomy (Down syndrome): 15 years later. J Theor Biol 181 1 (1996) 41-46
18. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., et al. The DNA sequence of human chromosome 21. Nature 405 6784 (2000) 311-319
19. Guttenbach M., Engel W., and Schmid M. Analysis of structural and numerical chromosome abnormalities in sperm of normal men and carriers of constitutional chromosome aberrations. A review. Hum Genet 100 1 (1997) 1-21
20. Simon R., and Bergemann A.D. Mouse models of Wolf-Hirschhorn syndrome. Am J Med Genet C: Semin Med Genet 148C 4 (2008) 275-280
21. Barisic N., Claeys K.G., Sirotkovic-Skerlev M., Lofgren A., Nelis E., De Jonghe P., et al. Charcot-Marie-Tooth disease: a clinico-genetic confrontation. Ann Hum Genet 72 Pt 3 (2008) 416-441
22. Arron J.R., Winslow M.M., Polleri A., Chang C.P., Wu H., Gao X., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441 7093 (2006) 595-600
23. Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 288 5475 (2000) 2357-2360
24. Gorska R., Gregorek H., Kowalski J., Laskus-Perendyk A., Syczewska M., and Madalinski K. Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J Clin Periodontol 30 12 (2003) 1046-1052
25. Cesar-Neto J.B., Duarte P.M., de Oliveira M.C., Casati M.Z., Tambeli C.H., Parada C.A., et al. Smoking modulates interferon-gamma expression in the gingival tissue of patients with chronic periodontitis. Eur J Oral Sci 114 5 (2006) 403-408
26. Honda T., Domon H., Okui T., Kajita K., Amanuma R., and Yamazaki K. Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. Clin Exp Immunol 144 1 (2006) 35-40
27. Kimura M., Cao X., Skurnick J., Cody M., Soteropoulos P., and Aviv A. Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. Free Radic Biol Med 39 3 (2005) 374-380
28. Rueda N., Mostany R., Pazos A., Florez J., and Martinez-Cue C. Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci Lett 380 1-2 (2005) 197-201
29. Moldrich R.X. A yeast model of Down syndrome. Int J Dev Neurosci 25 8 (2007) 539-543
30. Mustoe T.A., Pierce G.F., Thomason A., Gramates P., Sporn M.B., and Deuel T.F. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 237 4820 (1987) 1333-1336
31. Sporn M.B., and Roberts A.B. A major advance in the use of growth factors to enhance wound healing. J Clin Invest 92 6 (1993) 2565-2566
32. Miles R.H., Paxton T.P., Zacheis D., Dries D.J., and Gamelli R.L. Systemic administration of interferon-gamma impairs wound healing. J Surg Res 56 3 (1994) 288-294
33. Ishida Y., Kondo T., Takayasu T., Iwakura Y., and Mukaida N. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 172 3 (2004) 1848-1855
34. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408 6812 (2000) 600-605
35. Huang W., O'Keefe R.J., and Schwarz E.M. Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther 5 1 (2003) R49-59
36. Kotake S., Nanke Y., Mogi M., Kawamoto M., Furuya T., Yago T., et al. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 35 11 (2005) 3353-3363
37. Baker P.J., Dixon M., Evans R.T., Dufour L., Johnson E., and Roopenian D.C. CD4(+) T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect Immun 67 6 (1999) 2804-2809
38. Cenci S., Toraldo G., Weitzmann M.N., Roggia C., Gao Y., Qian W.P., et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 100 18 (2003) 10405-10410
39. Scheller J., Ohnesorge N., and Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 63 5 (2006) 321-329
40. Nishimura R., Moriyama K., Yasukawa K., Mundy G.R., and Yoneda T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res 13 5 (1998) 777-785
41. Kwan Tat S., Padrines M., Theoleyre S., Heymann D., and Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15 1 (2004) 49-60
42. Luckett L.R., and Gallucci R.M. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. Br J Dermatol 156 6 (2007) 1163-1171
43. Greca F.H., Souza Filho Z.A., Giovanini A., Camargo Junior C.A., Rubin M.R., and Silva R.F. Interleukin-6 (IL-6) influence on colonic anastomosis healing in rats. Acta Cir Bras 22 2 (2007) 110-114